StockNews.AI
QGEN
StockNews.AI
166 days

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

1. QGEN receives FDA clearance for QIAstat-Dx Gastrointestinal Panel 2 Mini B. 2. This is QGEN's second FDA clearance in 2025, enhancing its testing offerings.

2m saved
Insight
Article

FAQ

Why Bullish?

The FDA clearance boosts QGEN's market position, similar to past approvals that spurred sales growth.

How important is it?

The FDA approval is a significant development that can improve QGEN's revenue prospects.

Why Short Term?

Increased demand for testing can directly influence QGEN's quarterly performance soon.

Related Companies

BDXABTRMD
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN's second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 mont.

Related News